Scolr Pharma has signed a licensing agreement with RedHill Biopharma, granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on Scolr's proprietary extended delivery technology (CDT).

Ondansetron hydrochloride is the active ingredient in Zofran, GlaxoSmithKline’s drug to prevent chemotherapy and radiation related nausea and vomiting.

As per the terms of the licensing agreement, RedHill has agreed to make up front and additional payments to Scolr up to $600,000 based on achievement of certain regulatory milestones and the first commercial sale of the product and thereafter make payments to the company up to a maximum of $30m based on the aggregate net sales by RedHill of the licensed product over a 10 year period.

Stephen Turner, president and CEO of Scolr Pharma, said: “We believe RedHill is a strong partner to collaborate with for the further development of our CDT-based ondansetron tablet formulations. As Scolr continues to progress its pipeline of products, we will look for key strategic alliances, such as this licensing agreement with RedHill, to maximize the value of our pharmaceutical and nutritional product portfolio.”

Dror Ben-Asher, CEO of RedHill, said: “CDT-based ondansetron is the latest addition to RedHill’s fast-growing pipeline of late clinical-stage drugs. We are excited about our partnership with Scolr and intend to vigorously execute upon our development plans for CDT-based ondansetron.”